ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.

Bristol Myers Squibb at ASH 2024 (Alaric DeArment/Scrip)

With the mega-blockbuster immunomodulatory drug (IMiD) class on its way to fully losing patent protection, Bristol Myers Squibb is banking on the cereblon E3 ligase modulatory drug (CELMoD) class to replace it, and the firm has been releasing early data on a pair of myeloma assets from the program nearing the market.

New York-based BMS presented Phase I/II data for the CELMoD candidate mezigdomide looking at ways of combining it with other...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASH

More from Therapy Areas

Replimune CRL Could Hold Warning For Accelerated Approvals

 

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.